普罗丰迈迪克公司2025年季度报告

For the transition period fromCommission File Number:001-39032 Trading Symbol(s)Common Shares, No Par Value Per SharePROF Profound Medical Corp. (the “Company”) qualifies as a “Foreign Private Issuer,” as defined in Rule 3b-4 Item 1.Condensed Consolidated Financial StatementsCondensed Consolidated Balance Sheets as of March 31, 2025 and December 31, 2024 (Unaudited)1Condensed Consolidated Statements of Operations and Comprehensive Loss for the ThreeMonths Ended March 31, 2025 and 2024 (Unaudited)2Condensed Consolidated Statements of Shareholders’ Equity for the Three Months Ended March Current assets: Cash46,43354,912Trade and other receivables, net (note 3)5,9667,045Inventory (note 4)6,7955,801Prepaid expenses and deposits7181,307Total current assets59,91269,065Property and equipment, net (note 5)309Intangible assets, net (note 6)214Right-of-use assets, net342Deferred tax assets, net87Total assets60,86470,234LiabilitiesCurrent liabilities:Accounts payable1,0481,317Accrued expenses and other current liabilities (note 7)3,3502,835Deferred revenue636Long-term debt (note 8)—1,737Lease liabilities261Total current liabilities5,2956,565Deferred revenue85Long-term debt (note 8)4,4862,924 Accumulated Recent Accounting PronouncementsThe FASB issued ASU 2024-03 in November 2024 and ASU 2025-01 in January 2025 clarifying theeffective date of ASU 2024-03, Income Statement - Reporting Comprehensive Income - ExpenseDisaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses, an The major components of property and equipment, net, as of March 31, 2025 and December 31, 2024 consist of the following:March 31,December31,20252024$$Leasehold improvements542542Equipment under operating lease1,7052,2732,2472,815 31, 2024 - $199). During the three months ended March 31, 2025, the Company sold $78(three monthsended March 31, 2024 - $nil) of equipment under operating lease to a customer. Intangible assets Software0.89781,209 of the Company’s assets of whatever kind available for distribution to shareholders, after the rights ofthe creditors have been satisfied. Share options A summary of the share option activity during the period presented and the total number of share optionsoutstanding as at those dates are set forth below: Balance – December 31, 2024 Risk-free interest rate2.85%Dividend yield—The weighted average grant date fair values of share options granted for the three months ended March31, 2025 were C$6.32(three months ended March 31, 2024 - C$7.01). Long-term incentive plan customersLeasingTotal$$$Recurring - non-capital1,5212801,801Capital equipment820—8202,3412802,621For the three months ended March 31, 2024ContractswithcustomersLeasingTotal$$$ operations and comprehensive loss. The following tables represent total revenue by geographic area, based on the location of the location ofthe reporting entity for the three months ended March 31, 2025 and 2024, respectively: Recurring - non-capital2821,2932261,801Capital equipment570250—8208521,5432262,621 operations should be read in conjunction with our unaudited condensed consolidated financial statements andrelated notes that appear elsewhere in this report. In addition to historical financial information, the following discussion contains forward-looking statements that reflect our plans, estimates, assumptions and beliefs. Ouractual results could differ materially from those discussed in the forward-looking statements. Factors that couldcause or contribute to these differences include those discussed in the Risk Factors section of the Annual Report plans, potential growth opportunities, potential market opportunities, potential results of our development effortsor trials, and the effects of competition. Forward-looking statements include all statements that are not historical facts and can be identified by terms such as “anticipates,” “believes,” “could,” “seeks,” “estimates,”“expects,” “intends,” “may,” “plans,” “potential,” “predicts,” “projects,” “should,” “will,” “would” or similar expressions and the negatives of those terms. Given these uncertainties, you should not place unduereliance on these forward-looking statements. Also, forward-looking statements represent our management’s differ materially from those anticipated in these forward-looking statements, even if new information becomesavailable in the future. Unless stated otherwise, all references to “$” are to United States dollars in thousandsand all references to “C$” are to Canadian dollars in thousands. platform technologies and leveraging the healthcare system’s existing imaging infrastructure. Our lead product(the “TULSA-PRO system”) combines real-time MRI, robotically driven transurethral sweeping-action thermal single session that takes a few hours. Virtually all prostate shapes and sizes can be safely, effectively, andefficiently treated with TULSA. There is no bleeding associated with the procedure; no hospital stay is required;and most TUL